499 related articles for article (PubMed ID: 9133508)
21. Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function.
Schiffrin EL; Park JB; Pu Q
J Hypertens; 2002 Jan; 20(1):71-8. PubMed ID: 11791028
[TBL] [Abstract][Full Text] [Related]
22. Regional and racial differences in response to antihypertensive medication use in a randomized controlled trial of men with hypertension in the United States. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.
Cushman WC; Reda DJ; Perry HM; Williams D; Abdellatif M; Materson BJ
Arch Intern Med; 2000 Mar; 160(6):825-31. PubMed ID: 10737282
[TBL] [Abstract][Full Text] [Related]
23. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies.
Schmieder RE; Martus P; Klingbeil A
JAMA; 1996 May; 275(19):1507-13. PubMed ID: 8622227
[TBL] [Abstract][Full Text] [Related]
24. Effect of antihypertensive treatment on cardiac and subcutaneous artery structure: a comparison between calcium channel blocker and thiazide-based regimens.
Sihm I; Schroeder AP; Aalkjaer C; Mulvany MJ; Thygesen K; Lederballe O
Am J Hypertens; 1998 Mar; 11(3 Pt 1):263-71. PubMed ID: 9544865
[TBL] [Abstract][Full Text] [Related]
25. Comparison of actions of irbesartan versus atenolol on cardiac repolarization in hypertensive left ventricular hypertrophy: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation Versus Atenolol (SILVHIA).
Malmqvist K; Kahan T; Edner M; Bergfeldt L
Am J Cardiol; 2002 Nov; 90(10):1107-12. PubMed ID: 12423712
[TBL] [Abstract][Full Text] [Related]
26. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996).
Schmieder RE; Schlaich MP; Klingbeil AU; Martus P
Nephrol Dial Transplant; 1998 Mar; 13(3):564-9. PubMed ID: 9550628
[TBL] [Abstract][Full Text] [Related]
27. Double-blind, parallel, comparative multicentre study of a new combination of diltiazem and hydrochlorothiazide with individual components in patients with mild or moderate hypertension.
Manning G; Joy A; Mathias CJ; McDonald CJ; Millar-Craig MW
J Hum Hypertens; 1996 Jul; 10(7):443-8. PubMed ID: 8880557
[TBL] [Abstract][Full Text] [Related]
28. B2 bradykinin receptor (B2BKR) polymorphism and change in left ventricular mass in response to antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial.
Hallberg P; Lind L; Michaëlsson K; Karlsson J; Kurland L; Kahan T; Malmqvist K; Ohman KP; Nyström F; Melhus H
J Hypertens; 2003 Mar; 21(3):621-4. PubMed ID: 12640257
[TBL] [Abstract][Full Text] [Related]
29. The effects of antihypertensive combination therapy on lipid and glucose metabolism: hydrochlorothiazide plus sotalol vs. hydrochlorothiazide plus captopril.
Middeke M; Richter WO; Schwandt P; Holzgreve H
Int J Clin Pharmacol Ther; 1997 Jun; 35(6):231-4. PubMed ID: 9208337
[TBL] [Abstract][Full Text] [Related]
30. Correction of hypertensive cardiac remodelling: comparison of different antihypertensive therapies.
Almazov VA; Shlyakhto EV; Konrady AO; Macsimova TA; Zaharov DV; Rudomanov OG
Med Sci Monit; 2000; 6(2):309-13. PubMed ID: 11208328
[TBL] [Abstract][Full Text] [Related]
31. Proteinuria in mild to moderate hypertension: results of the VA cooperative study of six antihypertensive agents and placebo. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.
Preston RA; Materson BJ; Reda DJ; Hamburger RJ; Williams DW; Smith MH
Clin Nephrol; 1997 May; 47(5):310-5. PubMed ID: 9181278
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of different drug classes used to initiate antihypertensive treatment in black subjects: results of a randomized trial in Johannesburg, South Africa.
Sareli P; Radevski IV; Valtchanova ZP; Libhaber E; Candy GP; Den Hond E; Libhaber C; Skudicky D; Wang JG; Staessen JA
Arch Intern Med; 2001 Apr; 161(7):965-71. PubMed ID: 11295959
[TBL] [Abstract][Full Text] [Related]
33. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study evaluating regression of ventricular enlargement (preserve) trial.
Devereux RB; Palmieri V; Sharpe N; De Quattro V; Bella JN; de Simone G; Walker JF; Hahn RT; Dahlöf B
Circulation; 2001 Sep; 104(11):1248-54. PubMed ID: 11551875
[TBL] [Abstract][Full Text] [Related]
34. Hypertension in Diabetes Study IV. Therapeutic requirements to maintain tight blood pressure control.
Diabetologia; 1996 Dec; 39(12):1554-61. PubMed ID: 8960842
[TBL] [Abstract][Full Text] [Related]
35. Genetic Variants Associated With Uncontrolled Blood Pressure on Thiazide Diuretic/β-Blocker Combination Therapy in the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses) and INVEST (International Verapamil-SR Trandolapril Study) Trials.
Magvanjav O; Gong Y; McDonough CW; Chapman AB; Turner ST; Gums JG; Bailey KR; Boerwinkle E; Beitelshees AL; Tanaka T; Kubo M; Pepine CJ; Cooper-DeHoff RM; Johnson JA
J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29097388
[TBL] [Abstract][Full Text] [Related]
36. Combination antihypertensive therapy with terazosin and other antihypertensive agents: results of clinical trials.
Pool JL
Am Heart J; 1991 Sep; 122(3 Pt 2):926-31. PubMed ID: 1678924
[TBL] [Abstract][Full Text] [Related]
37. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study.
Pitt B; Reichek N; Willenbrock R; Zannad F; Phillips RA; Roniker B; Kleiman J; Krause S; Burns D; Williams GH
Circulation; 2003 Oct; 108(15):1831-8. PubMed ID: 14517164
[TBL] [Abstract][Full Text] [Related]
38. Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Wachtell K; Dahlöf B; Rokkedal J; Papademetriou V; Nieminen MS; Smith G; Gerdts E; Boman K; Bella JN; Devereux RB
Am Heart J; 2002 Dec; 144(6):1057-64. PubMed ID: 12486431
[TBL] [Abstract][Full Text] [Related]
39. Changes in left ventricular geometry during antihypertensive treatment.
Salvetti M; Paini A; Bertacchini F; Stassaldi D; Aggiusti C; Agabiti Rosei C; Bassetti D; Agabiti-Rosei E; Muiesan ML
Pharmacol Res; 2018 Aug; 134():193-199. PubMed ID: 29959031
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of the efficacy and tolerability of nitrendipine in reducing both pressure and left ventricular mass in hypertensive type 2 diabetic patients.
Scognamiglio R; Nosadini R; Marin M; Nisti S; Fasoli G; Palisi M; Frigato F; Virgili F; Carraro A; Crepaldi G
Diabetes Care; 1997 Aug; 20(8):1290-2. PubMed ID: 9250456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
